MegaPro Biomedical Co., Ltd (TPEX:6827)
Taiwan · Delayed Price · Currency is TWD 11.80
-0.05 (-0.42%)
At close: Feb 11, 2026
MegaPro Biomedical Company Description
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs.
It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor.
The company was founded in 2014 and is based in Zhubei, Taiwan.
MegaPro Biomedical Co., Ltd
| Country | Taiwan |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Jassy Wang |
Contact Details
Address: No. 66, Shengyi 5th Rd. Zhubei, 302 Taiwan | |
| Phone | 886 3 591 0360 |
| Website | megaprobio.com |
Stock Details
| Ticker Symbol | 6827 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Reporting Currency | TWD |
| ISIN Number | TW0006827009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jassy Wang | Chief Executive Officer |